This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TB vaccine - adjuvant IC31, Ag85B-ESAT-6 + IC31
Description: The HyVac4-IC31 vaccine contains Ag85B-ESAT-6 antigens discovered by Statens Serum Institute (SSI) and Intercell's adjuvant IC31.
IC31 is an adjuvant inducing both T-cell and B-cell responses with a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens, no conjugation is required.
Deal Structure: In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.
Additional information available to subscribers only: